Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Solid Tumors 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Advanced or Metastatic Solid Tumors 1

Interventions

Rituximab 155Cyclophosphamide 120fludarabine phosphate 71Whole-Body Irradiation 55Mycophenolic Acid 54Etoposide 53Peripheral Blood Stem Cell Transplantation 46fludarabine 45Melphalan 44Granulocyte Colony-Stimulating Factor 43Busulfan 43Tacrolimus 39Filgrastim 37Vincristine 33Cyclosporine 31Bendamustine Hydrochloride 31Prednisone 29Doxorubicin 29Antilymphocyte Serum 28Methotrexate 27Cytarabine 27Lenalidomide 23Carmustine 22Bortezomib 22plerixafor 20Dexamethasone 19Thiotepa 17Stem Cell Transplantation 17Radiotherapy 17tositumomab I-131 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Non-Hodgkin × TAK-981 × Clear all
NCT04074330 2024-06-14

A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Takeda

Phase 1/2 Terminated
38 enrolled 44 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡